MRVL vs PFE: Which Is the Better Buy?
Side-by-side comparison of Marvell Technology, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Marvell Technology, Inc. · Technology
$310.58
-18.5% upside to fair value
Grade D
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MRVL |
PFE |
| Current Price |
$310.58 |
$25.22 |
| Fair Value Estimate |
$253.23 |
$25.92 |
| Upside to Fair Value |
-18.5%
|
+2.8%
|
| Market Cap |
$271.7B |
$143.7B |
| Forward P/E |
105.7x
|
19.2x
|
| EV / EBITDA |
59.1x
|
12.3x
|
| Price / Sales |
31.2x
|
2.3x
|
| Price / FCF |
163.2x
|
15.2x
|
| Revenue Growth YoY |
+27.6%
|
+5.4%
|
| Gross Margin |
50.6%
|
69.3%
|
| Operating Margin |
16.2%
|
23.4%
|
| Return on Equity |
16.8%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
0.61%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Marvell Technology, Inc. designs and supplies semiconductor solutions primarily focused on data infrastructure markets including cloud, AI, carrier 5G, and custom silicon. The company benefits from a narrow but widening moat driven by strong IP and hyperscaler relationships, led by an experienced CEO with a track record of transformational M&A. Despite strong revenue growth of 42% year-over-year …
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
MRVL |
PFE |
| Zone Low |
$189.92 |
$19.44 |
| Zone High |
$215.25 |
$22.03 |
| In Buy Zone? |
No
|
No
|